by Ethan Perlstein | Apr 30, 2016 | Start-ups |
11-year old startup accelerator Y Combinator – “YC” for those in the know – has reached national (and international) acclaim for incubating today’s premier tech unicorns back when they were hatchlings. Companies with instant name recognition, like Airbnb (W09)...
by Ethan Perlstein | Apr 10, 2016 | Blogposts, Science |
Five months ago we introduced PERL101, one of our lead compounds for Niemann-Pick Type C (NPC) disease, in Part One. Here in Part Two we pick up the thread. On this journey we’ve progressed from nematodes to patient cells to mice with an unoptimized primary...
by Ethan Perlstein | Mar 26, 2016 | Last Month in Tweets |
“Last month in tweets” took a hiatus in the first quarter of 2016, but now it’s back! Why the break? The answer is Y Combinator. On January 4th, PLab was accepted into YC’s Winter 2016 batch. The all-consuming 3-month startup accelerator took...
by Ethan Perlstein | Dec 28, 2015 | Last Month in Tweets |
Feels like the last 12 months went by in a flash! When I wrote this post a year ago, we were just getting started in the lab but we had ambitious plans for the year to come. We set two big goals for 2015. First, to complete a two-species (nematode and fruit fly),...
by Ethan Perlstein | Nov 15, 2015 | Perlara science |
PERL101 is one of our lead compounds for Niemann-Pick C. We discovered it in a whole animal screen for small molecules that suppress the delayed onset of adulthood in NPC mutant nematode larvae. The path from primary screening hit to mouse validation studies usually...
